Oncology News | pharmaphorum

News

FDA approves second Neupogen biosimilar

Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym.

News

Gilead develops solid tumour cell therapy with Gadeta

Gilead has option to buy biotech if things go well

News

AbbVie raises hopes for blood cancer patients

AbbVie has filed its Venclexta (venetoclax) for a new use that it hopes could change the treatment of one of the most aggressive cancers – acute myeloid leukaemia (AML).

News

Taking lenient stance, NICE backs neuroblastoma drug

Body makes special case due to rarity of the disease

News

BMS immunotherapy combo approved in new colorectal use

Bristol-Myers Squibb’s Opdivo and Yervoy has become the first approved immunotherapy combination option for a group of patients with advanced colorectal cancer.

News

Fotivda approved in Scotland for kidney cancer

The Scottish Medicines Consortium (SMC) has recommended regular NHS funding for EUSA Pharma's kidney cancer drug Fotivda, enabling around 165 patients a year to access the treatment.

FDA approves second Neupogen biosimilar

Gilead develops solid tumour cell therapy with Gadeta

AbbVie raises hopes for blood cancer patients

Taking lenient stance, NICE backs neuroblastoma drug

BMS immunotherapy combo approved in new colorectal use

Fotivda approved in Scotland for kidney cancer

Curium strikes $8bn deal to buy radiopharma rival Lantheus

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks